4.7 Article

Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism

期刊

KIDNEY INTERNATIONAL
卷 88, 期 2, 页码 350-359

出版社

ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2015.72

关键词

hemodialysis; hyperparathyroidism; parathyroid hormone; survival

资金

  1. Bayer Yakuhin
  2. Kyowa Hakko Kirin
  3. Astellas Pharma
  4. Chugai Pharmaceutical
  5. Daiichi Sankyo
  6. Merck Sharp Dohme Corp.
  7. Mochida Pharmaceutical
  8. Teijin Pharma
  9. Torii Pharmaceutical
  10. Asahi Kasei Medical
  11. Baxter
  12. Fuso Pharmaceutical Industries
  13. GlaxoSmithKline K.K.
  14. Kissei Pharmaceutical
  15. Mitsubishi Tanabe Pharma
  16. Nippon Boehringer Ingelheim
  17. Otsuka Pharmaceutical
  18. Shionogi Pharmaceutical
  19. Taisho Pharmaceutical
  20. Takeda Pharmaceutical
  21. Ono Pharmaceutical

向作者/读者索取更多资源

Parathyroidectomy (PTx) drastically improves biochemical parameters and clinical symptoms related to severe secondary hyperparathyroidism (SHPT) but the effect of PTx on survival has not been adequately investigated. Here we analyzed data on 114,064 maintenance hemodialysis patients from a nationwide registry of the Japanese Society for Dialysis Therapy to evaluate the associations of severity of SHPT and history of PTx with 1-year all-cause and cardiovascular mortality. We then compared the mortality rate between 4428 patients who had undergone PTx and 4428 propensity score-matched patients who had not despite severe SHPT. During a 1-year follow-up, 7926 patients of the entire study population died, of whom 3607 died from cardiovascular disease. Among patients without a history of PTx, severe SHPT was associated with an increased risk for all-cause and cardiovascular mortality. However, such an increased risk of mortality was not observed among patients with a history of PTx. In the propensity score-matched analysis, patients who had undergone PTx had a 34% and 41% lower risk for all-cause and cardiovascular mortality, respectively, compared to the matched controls. The survival benefit associated with PTx was robust in several sensitivity analyses and consistent across subgroups, except for those who had persistent postoperative SHPT. Thus, successful PTx may reduce the risk for all-cause and cardiovascular mortality in hemodialysis patients with severe, uncontrolled SHPT.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据